Field efficacy and safety of a novel oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against naturally acquired gastrointestinal nematode infections in dogs presented as veterinary patients in Europe and the USA

Table 3 Efficacy of a single oral dose of Simparica Trio™ against natural Toxocara canis infections in dogs presented as veterinary patients in the USA

Sample^a	Treatment group^b	n	Egg count per gram feces		Efficacy
Sample^a	Treatment group^b	n	Geometric mean	95% CI	% Reduction	Test statistic^c
Pre-treatment	Simparica Trio™	83	272.98	156.11–476.79	–	–
Pre-treatment	Iver+Pyr	31	137.65	62.90–299.85	–	–
Post-treatment	Simparica Trio™	83	2.06	0.75–4.33	99.2	t₍₁₁₂₎= 17.18, P < 0.0001
Post-treatment	Iver+Pyr	31	1.89	0.33–5.27	98.6	t₍₁₁₂₎= 9.04, P < 0.0001

^aPre-treatment sample collected on Day-1 or Day 0 prior to treatment. Post-treatment sample collected between Day 8 and 14
^bSingle oral administration of Simparica Trio™ on Day 0 to provide dose ranges of 1.2–2.4 mg/kg sarolaner, 24–48 µg/kg moxidectin and 5–10 mg/kg pyrantel (as pamoate salt)
^cTest statistic and P-value for difference (pre-treatment – post-treatment) within group
Abbreviations: Iver, ivermectin; Pyr, pyrantel pamoate; CI, confidence interval

ISSN: 1756-3305